Dr. Edelman is Clinical Professor of Medicine in the Division of Geographic Medicine, Clinical Professor of Pediatrics in the Division of Infectious Diseases and Tropical Pediatrics, and Associate Director for Regulatory Affairs and Bioethics at the Center for Vaccine Development, University of Maryland School of Medicine. He received his A.B. degree (Phi Beta Kappa) and M.D. degree, cum laude and AOA, from Washington University, St. Louis, in 1962. He trained in Pathology and Medicine at The Johns Hopkins Hospital (1962-64) and in Medicine at Barnes Hospital, St. Louis (1964-65) and was a USPHS Fellow in Preventive Medicine and Viral Immunology at Case Western Reserve University (1965 to 1968).
Dr. Edelman served several assignments in the U.S. Army from 1968 to 1976. These assignment included: Chief, Communicable Diseases and Immunology Research Branch, U.S. Army Medical Research and Development Command, Office of the Surgeon General, Washington, D.C. (1968 1970); Acting Chief and Clinical Investigator, Department of Virology, Walter Reed Overseas Research Team at SEATO Medical Research Laboratory, Bangkok, Thailand (1970-1973); Chief, Medical Division, U.S. Army Medical Research Institute of Infectious Diseases; Director of Medical Activities, Fort Detrick, MD (1973 1974), Principal Investigator, Virology Division, US Army Medical Research Institute of Infectious Diseases (1974 1976). During this time he investigated the pathogenesis and epidemiology of arbovirus infections, the relationship between malnutrition and immunity, and he performed Phase 1 clinical trials of several viral vaccines, including vaccines against the bioterror agents, Tularemia and Venezuelan Equine Encephalomyelitis (VEE) virus.
Dr. Edelman moved to the NIAID in 1976, and until 1988, when he retired from the U.S. Public Health Service, he held many positions in administration, clinical research and teaching. He served as Deputy Director of the Microbiology and Infectious Disease Program at NIAID (a 180 million dollar extramural research program) and as Chief of the Clinical and Epidemiological Studies Branch. Despite his heavy administrative load, he continued to conduct clinical research, especially on Lyme disease, on the role of maternal vaginal infections as a cause of low infant birth weight, the epidemiology of AIDS, and clinical trials of new antifungal drugs. Dr. Edelman earned three service medals for his achievements during his tenure in the Army and USPHS.
At the University of Maryland since 1988, Dr. Edelman has served as a senior consultant on vaccine development to the biotechnology industry, major pharmaceutical houses, the World Health Organization, the NIH, the Department of Defense, the U.S. Agency for International Development, and the Gates Foundation's Malaria Vaccine Initiative and the Pediatric Dengue Vaccine Initiative. From 1988 until 2011, Dr Edelman was the Associate Director for Clinical Research at the CVD where he stimulated, coordinated and conducted clinical research. After semi-retirement in 2011, Dr Edelman has served as the Associate Director for Regulatory Affairs and Bioethics at the CVD. Dr. Edelman has been lead investigator on clinical trials of experimental vaccines, licensed vaccines and biologicals conducted in young or elderly volunteers against a wide variety of infectious diseases. These studies were/are supported by the NIH, the U.S. Army, private foundations and industry.
He was the P.I. of the University of Maryland Immunosenescence/Immunosupression Research Group funded by the NIAID. He has a recognized expertise in clinical trials of vaccine adjuvants. He has been interviewed widely and quoted in the public Media regarding vaccines against bioterror agents, influenza, dengue and other emerging infections. He was a member of the Advisory Committee on Dengue and Other Flavivirus Vaccines, World Health Organization, Geneva, for 5 years. Dr. Edelman directed the Travelers Health Clinic at the University of Maryland Medical Center for 20 years, and was Chairman of the Institutional Review Board, University of Maryland, Baltimore for 9 years. He initiated and currently directs the UMB’s Clinical Research Training and Mentoring Program for faculty. Dr. Edelman has co-edited one book, and lists 185 peer-reviewed papers, 28 book chapters, and 79 abstracts in his bibliography.
Clinical trials of vaccines or biologicals in healthy, young adult or elderly volunteers against many infectious diseases. These include emerging vector-borne infections (dengue, malaria, Lyme, Chikungunya), bioterror agents (Botulinum toxin and smallpox), diarrheal pathogens, hepatitis B, and respiratory pathogens (pneumococcus, respiratory syncytial virus, pertussis and influenza). He has conducted clinical research on immunosenescence, vaccines for the elderly (pneumococcus and influenza), and clinical trials of vaccine adjuvants. He has clinical expertise in travelers' health and travel vaccines, and in the regulations of Good Clinical Practice and the bioethics of clinical research.
- Travel Medicine
- Infectious Diseases
- Public Health
Selected peer-reviewed publications (Research and Reviews), 2008 - present:
R Edelman, J Hombach, "Guidelines for the Clinical Evaluation of Dengue Vaccines in Endemic Areas: Summary of a World Health Organization Steering Committee Report." Vaccine 26 (2008) 4113-4119.
Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW,Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R. "Phase 2 Clinical Trial of Three Formulations of Tetravalent Live-attenuated Dengue Vaccine in Flavivirus-Naïve Adults," Human Vaccines, 2009 Jan-Feb;5:1:33-40.
WH Chen, BF Kozlovsky, RB Effros, B Grubeck-Loebenstein, R Edelman, MB Sztein. “Vaccination in the elderly: an immunological perspective.” Trends in Immunology, 2009
RC Brady, JJ Treanor, RL Atmar, W Keitel, R Edelman, WH Chen, P Winokur, R Belshe, IL Graham, DL Noah, K Guo, H Hill. “Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly subjects.” Vaccine, 2009 13 Aug; 27:5091-5095.
SL. Hoffman, PF Billingsley, E James, A Richman, M Loyevsky, T Li, S Chakravarty, A Gunasekera, R Chattopadhyay, M Li, R Stafford, A Ahumada, JE Epstein, M Sedegah, S Reyes, TL Richie, KE Lyke, R Edelman, MB Laurens, CV Plowe, and B Kim Lee Sim. “Development of a metabolically active, non-replicating sporozoite Vaccine to Prevent Plasmodium falciparum Malaria.” Human Vaccines 6 (1), 97-106; Jan 2010.
GW Letson, P Singhasivanon, E Fernandez, N Abeysinghe, JJ Amador, HS Margolis, R Edelman. “Dengue Vaccine Trial Guidelines and the Role of Large-Scale, Post Proof-of-Concept Demonstration Projects in Bringing a Dengue Vaccine to Use in Dengue Endemic Areas.” Human Vaccines, 6:10, 1-8; November 2010.
KE Lyke, M Laurens, M Adams, P Billingsley, A Richman, M Loyevsky, S Chakravarty, CV Plowe, BK Lee Sim, R Edelman, SL Hoffman. “Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial.” PLoS ONE, Vol 5 (10); 1-10; October 2010.
D Trent, J Shin, J Hombach, P Minor (lead writers), A Barrett, D Bleijs, F Denamur, A Durbin, K Eckels, R Edelman, et al, (Working Group Advisors and peer reviewers). “Conference Report: WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11-12 May 2009.” Vaccine 2010, 28: 8246-8255.
WH Chen, AS Cross, R Edelman, MB Sztein, WC Blackwelder, MF Pasetti. Antibody
and Th1-type cell-mediated immune responses in elderly and young adults immunized
with the standard or a high dose influenza vaccine. Vaccine 2011, 29:2865-2873.
KB Anderson, RV Gibbons, R Edelman, KH Eckels, RJ Putnak, BL Innis, W Sun. ”Interference and Facilitation between Dengue Serotypes in a Tetravalent Live Dengue
Virus Vaccine Candidate.” Journal of Infectious Diseases 2011 (1 August), 204: 442-450
S.S. El-Kamary, M Billington, S Deitz, E Colby, H Rhinehart, Y Wu, W Blackwelder, R Edelman, A Lee, A King. Safety and tolerability of the Easy Vax™ Clinical Epidermal
Electroporation System in Healthy Adults. Molecular Therapy 2012 January;20(1):214-
Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley P, Laurens MB, Gunasekera A,
Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M,
Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett
JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe
CV, Loucq C, Edelman R, Richie TL, Seder RA, Hoffman SL. Live Attenuated Malaria
Vaccine Designed to Protect through Hepatic CD8+ T Cell Immunity. Science 28 Oct
2011: Volume 334, No. 6055, pp. 475-480.
AD Bentsi-Enchilla, J Schmitz, R Edelman, A Durbin, JT. Roehrig, PG. Smith, J
Hombach, J Farrar. “Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation.” Vaccine (Published 6 April
2013, DOI: .
Recent Book Chapters:
R Edelman. "Guidelines for the Clinical Evaluation of Dengue Vaccines in Endemic areas." In: Who Initiative for Vaccine Research (IVR). World Health Organization, Geneva, Switzerland, September 2008. WHO/IVB/08.12
Edelman R, Whitehead SS, Vaughn DW. "Vaccine Strategies to Prevent Dengue." In: New Generation Vaccines, 4th Edition, MM Levine, G Dougan, MF Good, MA Liu, GJ Nable, JP Nataro, and R Rappuoli. (Eds.) Informa healthcare, New York, 2009.
Basnyat B, Cumbo T, Edelman R. Infections at High Altitude. In: Infections of Leisure, 4th Edition, D Schlossberg, (Ed), ASM Press, Washington, D.C., 2009
E Harris, J Hombach, J Lazdins-Held (lead writers), B Canard, A Durbin, R Edelman, M Guzman, J Roehrig, S Vasudevan (Advisors and peer reviewers). Chapter 6, New Avenues, In: DENGUE: Guidelines for Diagnosis, Treatment, Prevention and Control, New edition, 2009, TDR, World Health Organization, Geneva, Switzerland.
Clinical Research and the Law. Patricia M. Tereskerz, JD, PhD; Consulting Clinical Editors: Robert Edelman, MD and Ross McKinney, Jr. MD., Wiley–Blackwell Publisher, Oxford, UK, May, 2012.